Retatrutide

Product Info

Retatrutide is an investigational peptide studied for its activity across three metabolically relevant receptor systems: the glucose-dependent insulinotropic polypeptide receptor, glucagon-like peptide-1 receptor and glucagon receptor.  

Research Overview

Unlike single- or dual-receptor agonists, Retatrutide has been designed as one molecule capable of activating GIP, GLP-1 and glucagon receptors. This makes it relevant to laboratory studies examining how combined receptor signalling influences cellular metabolism, energy regulation and glucose-associated pathways. Retatrutide remains an investigational compound. Its safety, quality and effectiveness continue to be evaluated through controlled clinical research, and it is not currently an authorised medicine in the United Kingdom.  

Key Characteristics

• Investigational triple-receptor agonist
• Activity at GIP, GLP-1 and glucagon receptors
• Relevant to multi-receptor signalling research
• Suitable for controlled biochemical and cell-based investigation

 

Product Information

• Product name: Retatrutide
• Development reference: LY3437943
• Classification: Triple hormone-receptor agonist
• Available sizes: 10mg, 30mg and 60mg
• Presentation: Sealed research vial

 

Handling and Storage

Keep the sealed material protected from direct light, moisture and unnecessary temperature variation. Preparation, analytical testing, storage and disposal should only be undertaken by suitably qualified personnel in accordance with the product label, batch documentation and validated laboratory procedures.  

Research and Regulatory Status

Retatrutide is an investigational compound that is not authorised as a medicine in the United Kingdom. This material must not be administered to humans or animals and must not be used for self-experimentation, weight management, medical treatment or any other personal purpose.